Table 2. Minimum inhibitory concentrations (MIC) of clinical isolates of Candida (n=130) to various antifungal drugs.

Antifungal	MIC range (μg/mL)*
	0.065	0.125	0.25	0.5	1	2	4	8	16	32	64
Fluconazole
C. albicans					84	4	4	10	1		6
C. glabrata					5		3	1			2
C. tropicalis					5			2			2
C. dubliniensis					2
Voriconazole
C. albicans		96	4	1	4	1	1	2
C. glabrata		9					2
C. tropicalis		7						1	1
C. dubliniensis		2
Caspofungin
C. albicans			102		3	4	4
C. glabrata			9				2
C. tropicalis			6				2	1
C. dubliniensis			2
Micafungin
C. albicans	101	2		2			4
C. glabrata	6	3					2
C. tropicalis	6	1					2
C. dubliniensis	2
Amphotericin B
C. albicans			72	31	2		4
C. glabrata			3	6					2
C. tropicalis			6	1					2
C. dubliniensis			2
Flucytosine
C. albicans					103			2	2		2
C. glabrata					7	3				1
C. tropicalis					6	1	1				1
C. dubliniensis					2

^*MIC breakpoints' interpretation: fluconazole susceptible: MIC ≤8 µg/mL; fluconazole intermediate: MIC 16-32 µg/mL; fluconazole resistant: MIC ≥64 µg/mL; micafungin and caspofungin susceptible: MIC ≤0.25; micafungin and caspofungin intermediate: no clinical breakpoint; micafungin and caspofungin resistant: MIC ≥1 µg/mL; flucytosine susceptible: MIC ≤4 µg/mL; flucytosine intermediate: MIC 8-16 µg/mL; flucytosine resistant: MIC ≥32 µg/mL; voriconazole susceptible: MIC ≤1 µg/mL; voriconazole intermediate: MIC 2 µg/mL; voriconazole resistant: MIC≥ 4 µg/mL; amphotericin B susceptible: MIC ≤1 µg/mL; amphotericin B Intermediate: no clinical breakpoint; amphotericin B resistant: MIC >1 µg/mL.